For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 0 | 0 | - | - |
| Research and development | 7,020 | 4,103 | 2,830 | 3,224 |
| General and administrative | 3,679 | 3,618 | 3,673 | 3,282 |
| Total operating expenses | 10,699 | 7,721 | 6,503 | 6,506 |
| Operating loss | -10,699 | -7,721 | -6,503 | -6,506 |
| Other (expense) income, net-Nonrelated Party | -34 | 12 | - | - |
| Other expense, net | - | - | -45 | 85 |
| Other (expense) income, net-Related Party | -6 | 54 | - | - |
| Interest income | 399 | 275 | 331 | 504 |
| Interest expense | 5 | - | - | - |
| Loss before income taxes and noncontrolling interest | -10,345 | -7,380 | -6,217 | -5,840 |
| Income tax provision | 0 | 0 | - | - |
| Net loss before noncontrolling interest | -10,345 | -7,380 | -6,217 | -5,840 |
| Less net loss attributable to noncontrolling interests | -1,647 | -1,334 | -1,125 | -1,057 |
| Net loss attributable to vtv therapeutics inc | -8,698 | -6,046 | -5,092 | -4,783 |
| Basic eps | - | - | -0.77 | -0.88 |
| Diluted eps | - | - | -0.77 | -0.88 |
| Basic average shares | - | - | 6,582,844 | 5,456,307 |
| Diluted average shares | - | - | 6,582,844 | 5,456,307 |
| Net loss per share of vtv therapeutics inc. class a common stock, basic (in usd per share) | -1.08 | - | - | - |
| Net loss per share of vtv therapeutics inc. class a common stock, diluted (in usd per share) | -1.08 | - | - | - |
| Weighted average number of vtv therapeutics inc. class a common stock, basic (in shares) | 8,055,940 | - | - | - |
| Weighted average number of vtv therapeutics inc. class a common stock, diluted (in shares) | 8,055,940 | - | - | - |
vTv Therapeutics Inc. (VTVT)
vTv Therapeutics Inc. (VTVT)